Rapid Response Agents Against Filovirus Outbreaks Using Vectored Immunoprophylaxis
使用载体免疫预防针对丝状病毒爆发的快速反应剂
基本信息
- 批准号:9200868
- 负责人:
- 金额:$ 24.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-01 至 2017-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAnimal ModelAnimalsAntibodiesBioterrorismCategoriesCaviaCommunicable DiseasesDNADemocratic Republic of the CongoDengue VirusDisease OutbreaksEbola VaccinesEbola virusEnzyme-Linked Immunosorbent AssayEpidemicEuropeFilovirusGene Therapy AgentGene TransferGenesGlycoproteinsGoalsGuineaHIVHIV AntibodiesHIV prevention trialHeadHealth PersonnelHumanImmunofluorescence ImmunologicImmunoprecipitationIn VitroIndividualInfectionInfectious AgentInjection of therapeutic agentInternationalInvestigationKineticsLiberiaLifeMacacaModelingMonoclonal AntibodiesMusPassive ImmunizationPatternPhasePlasmidsPopulationPrevention approachProductionReagentReportingSierra LeoneSystemTechnologyTestingTherapeuticTimeUnited StatesVaccinesViral Hemorrhagic FeversVirusWestern BlottingWorkabstractingadeno-associated viral vectorbaseclinical efficacyefficacy evaluationhigh riskimmunoprophylaxisin vivomanmortalitymouse modelmurine monoclonal antibodynonhuman primateoptimismprophylacticpublic health emergencyresponse
项目摘要
Summarty / Abstract
Vectored immunoprophylaxis, or antibody gene transfer for infectious disease, is a promising new strategy to
provide protection against high risk infectious agents, supplementing vaccine and passive immunization efforts.
It has been demonstrated to be effective against HIV and Dengue virus in animal models, and there is currently
an ongoing human trial for HIV prevention in high-risk individuals with an adeno-associated viral vector (AAV)
delivering the gene for a broadly neutralizing HIV antibody. We propose to expand these efforts to
the filoviruses, starting with the Ebolavirus Zaire (EBOV). EBOV causes severe hemorrhagic fever, with a high
mortality between 30 and 90%, depending on the virus. Although the recent EBOV epidemic appears to be
waning, the outbreak was classified by the WHO as "an international public health emergency." In addition,
Ebolavirus is a potential bioterrorism agent (Category A). While recent reports suggest optimism for an Ebola
vaccine, these are early trials with much work to be done to prove efficacy, and to characterize the onset of
protection and durability. Passive immunization has shown great promise against EBOV in a therapeutic
setting, however, production capabilities are not yet available for protection of a large segment of the
population, and passive immunization requires repeated administration if used in a prophylactic setting. As
such, there is an ongoing need for increasing the repertoire of immunoprotectants such as vectored antibodies.
摘要/摘要
载体免疫预防,或用于传染病的抗体基因转移,是一种有前途的新策略,
提供针对高风险传染性病原体的保护,补充疫苗和被动免疫工作。
它已被证明是有效的抗艾滋病毒和登革热病毒的动物模型,目前有
一项正在进行的使用腺相关病毒载体(AAV)在高危人群中预防HIV的人体试验
传递一种广泛中和的HIV抗体的基因。我们建议扩大这些努力,
丝状病毒,从扎伊尔埃博拉病毒(EBOV)开始。EBOV引起严重的出血热,
死亡率在30%到90%之间,取决于病毒。虽然最近的EBOV流行似乎是
随着疫情逐渐减弱,世界卫生组织将此次疫情列为“国际公共卫生紧急事件”。“此外,
埃博拉病毒是一种潜在的生物恐怖主义制剂(A类)。虽然最近的报告显示埃博拉病毒的乐观情绪
疫苗,这些都是早期试验,有很多工作要做,以证明疗效,并表征发病
保护和耐用性。被动免疫在治疗EBOV方面显示出巨大的前景。
然而,在这种情况下,生产能力尚不足以保护大部分的
被动免疫如果用于预防性环境则需要重复施用。作为
因此一直需要增加免疫保护剂如载体化抗体的库。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Larry Zeitlin其他文献
Larry Zeitlin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Larry Zeitlin', 18)}}的其他基金
Core B - MappBiopharmaceutical, Inc.
核心 B - MappBiopharmaceutical, Inc.
- 批准号:
10362728 - 财政年份:2019
- 资助金额:
$ 24.02万 - 项目类别:
Core B - MappBiopharmaceutical, Inc.
核心 B - MappBiopharmaceutical, Inc.
- 批准号:
10581494 - 财政年份:2019
- 资助金额:
$ 24.02万 - 项目类别:
Development of highly potent human monoclonal for RSV immuno-prophylaxis
开发用于 RSV 免疫预防的高效人单克隆抗体
- 批准号:
10208698 - 财政年份:2018
- 资助金额:
$ 24.02万 - 项目类别:
Development of highly potent human monoclonal for RSV immuno-prophylaxis
开发用于 RSV 免疫预防的高效人单克隆抗体
- 批准号:
10080251 - 财政年份:2018
- 资助金额:
$ 24.02万 - 项目类别:
Development of highly potent human monoclonal for RSV immuno-prophylaxis
开发用于 RSV 免疫预防的高效人单克隆抗体
- 批准号:
10447760 - 财政年份:2018
- 资助金额:
$ 24.02万 - 项目类别:
An Immunoprotectant for Argentine Hemorrhagic Fever
阿根廷出血热的免疫保护剂
- 批准号:
8840490 - 财政年份:2014
- 资助金额:
$ 24.02万 - 项目类别:
An Immunoprotectant for Argentine Hemorrhagic Fever
阿根廷出血热的免疫保护剂
- 批准号:
8692502 - 财政年份:2014
- 资助金额:
$ 24.02万 - 项目类别:
An Antibody Immunoprotectant for Category B Toxins
B 类毒素的抗体免疫保护剂
- 批准号:
8484785 - 财政年份:2012
- 资助金额:
$ 24.02万 - 项目类别:
An Antibody Immunoprotectant for Category B Toxins
B 类毒素的抗体免疫保护剂
- 批准号:
9067312 - 财政年份:2012
- 资助金额:
$ 24.02万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists